Press Releases Year None2024202320222021 June 11, 2024 NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office June 7, 2024 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 29, 2024 NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June May 21, 2024 NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings May 9, 2024 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results May 3, 2024 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 2, 2024 NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 April 9, 2024 NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease April 1, 2024 NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer March 25, 2024 NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Next page next › Last page last » Displaying 21 - 30 of 38
June 11, 2024 NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
May 21, 2024 NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
May 9, 2024 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
April 9, 2024 NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
April 1, 2024 NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
March 25, 2024 NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
